5-(5-((2S)-2-tert-Butoxycarbonyl-2-(naphthalene-2-sulfonylamino)-ethyl)-thiophen-2-yl)-pentanoic Acid | 344620-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-(5-((2S)-2-tert-Butoxycarbonyl-2-(naphthalene-2-sulfonylamino)-ethyl)-thiophen-2-yl)-pentanoic Acid
• 英文别名: 5-[5-[(2S)-3-[(2-methylpropan-2-yl)oxy]-2-(naphthalen-2-ylsulfonylamino)-3-oxopropyl]thiophen-2-yl]pentanoic acid
• CAS: 344620-00-4
• 化学式: C₂₆H₃₁NO₆S₂
• 分子量: 517.667
• InChiKey: QPXATBNYYXVTEV-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  146
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Thienylalanine derivatives as inhibitors of cell adhesion
  申请人：——

  公开号：US20030105080A1

  公开（公告）日：2003-06-05

  The present invention relates to compounds of formula (I), in which A, B, X, Y, R 1 , R 2 , R 3 and n have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention fruthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式（I）的化合物，其中A、B、X、Y、R1、R2、R3和n具有所述索引中指示的含义。式（I）的化合物是有价值的药理活性化合物。它们是vitronectin受体拮抗剂和细胞黏附抑制剂，适用于基于细胞-细胞或细胞-基质相互作用过程中vitronectin受体和它们的配体之间相互作用的疾病的治疗和预防，或者可以通过影响这些相互作用来预防、缓解或治愈这些疾病。例如，它们可以应用于通过抑制骨吸收细胞破骨细胞来治疗和预防骨质疏松症，或者用于抑制不良血管生成或血管平滑肌细胞增殖。此外，本发明还涉及式（I）的化合物的制备过程，它们的使用，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1240161A1

  公开（公告）日：2002-09-18
• US6762190B2
  申请人：——

  公开号：US6762190B2

  公开（公告）日：2004-07-13
• [EN] THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION<br/>[FR] DERIVES DE THIENYLALANINE INHIBITEURS D'ADHESION CELLULAIRE
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2001044237A1

  公开（公告）日：2001-06-21

  The present invention relates to compounds of formula (I), in which A, B, X, Y, R?1, R2, R3¿ and n have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention fruthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.